Richard Markus, Dantari CEO

Am­gen vet's new biotech nets $47M Se­ries A for poly­mer-based AD­Cs

Cal­i­for­nia-based can­cer start­up Dan­tari an­nounced a $47 mil­lion Se­ries A fi­nanc­ing Thurs­day in its push to de­vel­op an­ti­body-drug con­ju­gates with its own spin on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.